Table 4.
Clinical outcomes by treatment and baseline estimated glomerular filtration rate
| Clinical outcome | Kaplan–Meier event rate at 1 year | Kaplan–Meier event rate at 2 years | HR (95% CI) | Interaction P‐value | ||||
|---|---|---|---|---|---|---|---|---|
| Vericiguat(%) | Placebo(%) | ARR [%] (95% CI) | Vericiguat(%) | Placebo(%) | ARR [%] (95% CI) | |||
| HF hospitalization or CV death | 0.17 | |||||||
| eGFR ≤30 mL/min/1.73 m2 | 47.98 | 47.88 | 0.10 (−9.09–9.28) | 70.40 | 62.51 | 7.89 (−3.91–19.69) | 1.06 (0.84–1.35) | |
| 30 < eGFR ≤60 mL/min/1.73 m2 | 33.65 | 37.65 | −4.00 (−8.29–0.28) | 45.06 | 52.05 | −6.99 (−12.37 to −1.60) | 0.83 (0.72–0.95) | |
| eGFR>60 mL/min/1.73 m2 | 25.25 | 28.90 | −3.65 (−7.44–0.15) | 36.68 | 38.42 | −1.75 (−6.75–3.26) | 0.93 (0.80–1.08) | |
| HF hospitalization or all‐cause death | 0.22 | |||||||
| eGFR ≤30 mL/min/1.73 m2 | 50.32 | 52.18 | −1.86 (−10.86–7.15) | 72.88 | 67.82 | 5.06 (−5.90–16.02) | 1.01 (0.80–1.26) | |
| 30 < eGFR ≤60 mL/min/1.73 m2 | 35.13 | 39.07 | −3.94 (−8.23–0.35) | 46.86 | 54.23 | −7.37 (−12.70 to −2.04) | 0.83 (0.73–0.95) | |
| eGFR >60 mL/min/1.73 m2 | 26.57 | 29.63 | −3.06 (−6.89–0.77) | 38.86 | 40.23 | −1.38 (−6.43–3.67) | 0.95 (0.83–1.10) | |
| CV death | 0.67 | |||||||
| eGFR ≤30 mL/min/1.73 m2 | 17.88 | 23.64 | −5.76 (−13.26–1.73) | 37.56 | 36.27 | 1.28 (−10.43–13.00) | 0.90 (0.64–1.26) | |
| 30 < eGFR ≤60 mL/min/1.73 m2 | 13.13 | 14.22 | −1.09 (−4.21–2.02) | 23.05 | 25.80 | −2.75 (−7.52–2.02) | 0.87 (0.71–1.06) | |
| eGFR >60 mL/min/1.73 m2 | 10.49 | 10.68 | −0.18 (−2.82–2.46) | 16.96 | 18.65 | −1.69 (−5.76–2.38) | 0.99 (0.80–1.24) | |
ARR, absolute risk reduction; CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio.